Printer Friendly

PETRICCIANI JOINS GENETICS INSTITUTE AS REGULATORY AFFAIRS VICE PRESIDENT

 PETRICCIANI JOINS GENETICS INSTITUTE
 AS REGULATORY AFFAIRS VICE PRESIDENT
 CAMBRIDGE, Mass., April 7 /PRNewswire/ -- Genetics Institute, Inc. (NASDAQ: GENIZ) announced today that John Petricciani, M.D. will be joining the company in June in the newly-created position of vice president of regulatory affairs.
 Petricciani has extensive experience in the regulation of pharmaceutical products and has previously held a variety of government positions. These include the U.S. Public Health Service, where he served as deputy director in the Office of the Assistant Secretary for Health, the World Health Organization where he served as the chief of biologicals, and the U.S. Food and Drug Administration where he served as director of biologics.
 Immediately prior to joining Genetics Institute, Petricciani was the vice president for medical and regulatory affairs for the Pharmaceutical Manufacturers Association. In this position he gained wide recognition for his work to improve mechanisms for drug reimbursement and to improve the drug approval process.
 "Now, as we move toward commercializing several important new biopharmaceuticals, the experience and perspective John brings are valuable for our organization. We expect John Petricciani to play a critical role in the management of our company," commented Gabriel Schmergel, president and CEO of Genetics Institute.
 Genetics Institute is a leading biopharmaceutical firm engaged in the discovery and development of human pharmaceuticals through recombinant DNA and other technologies. The company has a diversified portfolio of licensed and proprietary pharmaceutical products.
 -0- 4/7/92
 /CONTACT: Melinda Lindquist of Genetics Institute, 617-876-1170/
 (GENIZ) CO: Genetics Institute, Inc. ST: Massachusetts IN: MTC SU: PER


EG -- NE005 -- 5755 04/07/92 10:29 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 7, 1992
Words:266
Previous Article:CASCADE MEDICAL SIGNS EUROPEAN DISTRIBUTION AGREEMENTS
Next Article:GREAT WESTERN BANK, FANNIE MAE TO PROVIDE $6 BILLION IN MORTGAGE FINANCING FOR HOME BUYERS IN 20 STATES


Related Articles
BEAURLINE PROMOTED TO VICE PRESIDENT OF GV MEDICAL
GENETICS INSTITUTE PLANS $55 MILLION FACILITY EXPANSION IN MASSACHUSETTS
GENETICS INSTITUTE AND SCIGENICS PLAN TO FILE AMENDED PROTOCOL FOR TESTING OF M-CSF AS CHOLESTEROL LOWERING AGENT
PATRICK GAGE, PH.D. TO BECOME GENETICS INSTITUTE'S CHIEF OPERATING OFFICER; OTHER OFFICERS APPOINTED
MALASKA JOINS TARGETED GENETICS AS ASSOCIATE DIRECTOR OF REGULATORY AFFAIRS
Targeted Genetics Announces Executive Appointments.
Vertex Announces Appointment of Dr. Neil Kirby As HIV Program Executive.
Vitex Strengthens Clinical and Regulatory Management Team.
Schering-Plough Research Institute Appoints Thomas Koestler Executive Vice President, Worldwide Regulatory Affairs, Worldwide Research Quality...
TKT Announces Executive Promotions.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters